Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Gold Prices Rise on Weaker Dollar and Ceasefire Hopes 
Federal Reserve Probes Big Banks Over Private Credit Exposure Amid Growing Systemic Risk Concerns 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China Set to Exit Deflation Cycle in Early 2026, ANZ Analysts Say 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Gulf Ceasefire Cracks Rattle Asian Markets and Push Oil Prices Higher 
Trump Claims Oil Tankers Heading to U.S. Amid Iran War and Strait of Hormuz Crisis 
U.S. Inflation Surges in March as Iran War and Tariffs Drive Prices Higher 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Markets Post Strong Weekly Gains Despite Middle East Tensions and Rising Energy Prices 
White House Warns Staff Over Insider Trading Amid Suspicious Oil Market Bets 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
